For its third fiscal quarter (ending September 30), Tandem Diabetes Care Inc (NASDAQ: TNDM) has reported a -31% decline in E.P.S. from $-0.51 a year ago to $-0.35 in the current quarter. For the latest four quarters through September 30, E.P.S. were $-1.94 versus $-3.22 for the same period a year ago — a decline of -40%.
Recent Price Action
On 11/6/24, Tandem Diabetes Care Inc (NASDAQ: TNDM) stock enjoyed a large increase of 3.4%, closing at $34.24. Moreover, this advance was accompanied by exceptionally high trading volume at 261% of normal. The stock has risen 4.0% during the last week and has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
TNDM is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Tandem Diabetes Care has a current Value Trend Rating of C (Low Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Tandem Diabetes Care has a very low Appreciation Score of 7 but a good Power Rating of 83, triggering the Low Neutral Value Trend Rating.
Rating Review
In light of this new information and positive market action we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment